N-((8-hydroxyquinolin-7-yl)(phenyl)methyl)propionamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-((8-hydroxyquinolin-7-yl)(phenyl)methyl)propionamide
• 英文别名: N-[(8-Hydroxy-7-quinolinyl)phenylmethyl]propanamide；N-[(8-hydroxyquinolin-7-yl)-phenylmethyl]propanamide
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.364
• InChiKey: ZFUPNSFODRGWDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY
  申请人：Jnana Therapeutics, Inc.

  公开号：US20210299070A1

  公开（公告）日：2021-09-30

  Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

  揭示了治疗肌酸转运蛋白缺乏症的方法，包括向需要的哺乳动物施用增加突变型或野生型肌酸转运蛋白对底物转运的化合物的治疗有效量。还披露了增加鸟氨酸乙酸或其盐跨越哺乳动物血脑屏障的方法，以及减少哺乳动物细胞中鸟氨酸乙酸或其盐的积累或浓度的方法。
• SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS
  申请人：Jnana Therapeutics, Inc.

  公开号：US20210300898A1

  公开（公告）日：2021-09-30

  Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

  揭示了用于治疗或预防与蛋白质突变相关的疾病或紊乱的化合物、组合物和方法。
• Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
  申请人：CORNELL UNIVERSITY

  公开号：US10716783B2

  公开（公告）日：2020-07-21

  Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R2 is independently selected from said cyclic groups of R1 and acyclic hydrocarbon groups R5 containing up to twenty carbon atoms; R3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R6 and R7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.

  治疗神经细胞损伤患者的方法，该方法包括向患者施用有效量的具有下通式(1)的HIF脯氨酰-4-羟化酶抑制化合物 其中R1是含有至少三个至多七个碳原子的环状基团，任选含有一个或多个选自O、N和S的杂原子，并任选通过连接基团连接到所示碳原子；R2 独立地选自 R1 的环状基团和含有多达 20 个碳原子的无环烃基团 R5；R3 选自氢原子和含有多达 6 个碳原子的烃基团；R6 和 R7 独立地选自氢原子、含有多达 3 个碳原子的烃基团、卤素原子和极性基团及其亚甲基连接型；以及 t 为 0 或 1。
• PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY
  申请人：Cornell University

  公开号：EP3079697B1

  公开（公告）日：2021-02-03
• PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM
  申请人：CORNELL UNIVERSITY

  公开号：US20160317526A1

  公开（公告）日：2016-11-03

  Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R 1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R 2 is independently selected from said cyclic groups of R 1 and acyclic hydrocarbon groups R 5 containing up to twenty carbon atoms; R 3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R 6 and R 7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.